ES104

Elpiscience (Suzhou) Biopharma, Ltd. · Phase 1 active Small molecule

ES104 is a novel therapeutic agent under development by Elpiscience (Suzhou) Biopharma, Ltd. for the treatment of metastatic colorectal cancer. Currently in Phase 1 and Phase 2 trials, ES104 has shown promising preliminary results. The drug targets a specific molecular pathway and is being evaluated for its safety and efficacy in a small patient cohort.

At a glance

Generic name	ES104
Sponsor	Elpiscience (Suzhou) Biopharma, Ltd.
Modality	Small molecule
Phase	Phase 1

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

ES104 CI brief — competitive landscape report
ES104 updates RSS · CI watch RSS
Elpiscience (Suzhou) Biopharma, Ltd. portfolio CI